Delcath Systems, Inc. (DCTH)
-NasdaqCM | Prev Close: | 0.31 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 1.30 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 4-Nov-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 0.29 - 2.38 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 1,297,600 |
|---|
| Market Cap: | 29.76M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- On The Fly: After Hours Moversat theflyonthewall.com(Tue, Oct 1)
- Delcath gets special FDA designation for therapyAP(Tue, Oct 1)
- InPlay: Delcath: FDA grants orphan drug designation to Delcath Systems for use of melphalan hydrochloride in HCCBriefing.com(Tue, Oct 1)
- U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO DELCATH SYSTEMS FOR USE OF MELPHALAN HYDROCHLORIDE IN HCCThomson Reuters ONE(Tue, Oct 1)
- Varian Unveils New Oncology SoftwareZacks(Wed, Sep 25)
- Intuitive Surgical's Firefly Gets FDA ApprovalZacks(Tue, Sep 24)
- ARAY Platform Gains FootholdZacks(Mon, Sep 23)
- Radiosurgery Suite Boosts Varian MedicalZacks(Mon, Sep 23)
- Thoratec Upped to NeutralZacks(Fri, Sep 20)
- PerkinElmer Upgraded to NeutralZacks(Thu, Sep 19)
- DELCATH SYSTEMS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibitEDGAR Online(Mon, Sep 16)
- [$$] Charting the Marketat Barrons.com(Sat, Sep 14)
- DELCATH SYSTEMS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Fri, Sep 13)
- CFO Moves: Brooks Automation, Suntech Power, Delcath Systemsat The Wall Street Journal(Fri, Sep 13)
- DELCATH SYSTEMS BOARD OF DIRECTORS IMPLEMENTS LEADERSHIP TRANSITION PLANThomson Reuters ONE(Fri, Sep 13)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 47.92 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.37 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.08 |
|---|
| Mean Recommendation*: | 3.3 |
|---|
| PEG Ratio (5 yr expected): | -0.06 |
|---|
Business Summary
Delcath Systems, Inc. operates as a specialty pharmaceutical and medical device company focusing on the field of oncology. The companys proprietary technology enables the administration of high-dose chemotherapy and other therapeutic agents ...
View More